Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Talha BadarAhmad NanaaEhab AtallahRory M ShallisSacchi de Camargo Correia GuilhermeAaron D GoldbergAntoine N SalibaAnand Ashwin PatelJan Philipp BewersdorfAdam S DuVallDanielle BradshawYasmin M AbazaGuru Subramanian Guru MurthyNeil PalmisianoAmer M ZeidanVamsi K KotaMark R LitzowPublished in: Blood cancer journal (2024)